RCM — R1 RCM Share Price
- $6.04bn
- $8.09bn
- $2.25bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.15 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 32.43 | ||
Price to Sales | 2.45 | ||
EV to EBITDA | 19.47 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 1.92% | ||
Return on Equity | -2.2% | ||
Operating Margin | 4.14% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1,186.1 | 1,270.8 | 1,474.6 | 1,806.4 | 2,254.2 | 2,573.21 | 2,909.27 | 21.02% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | +34.97 | n/a | n/a | +8.02 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
R1 RCM Inc. is a provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups. The Company’s scalable operating models seamlessly complement a healthcare organization’s infrastructure, driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. The Company delivers solutions to customers through technology, intellectual property (IP), global scale, and operational excellence. Its Intelligent Automation modernizes processes, removes friction, and simplifies revenue cycle management (RCM). Its use of artificial intelligence (AI) in its platform depends on the availability and pricing of equipment and technical infrastructure from third parties, including Microsoft Azure. It serves over 3,700 hospitals, including 93 of the top 100 health systems, and over 30,000 physicians.
Directors
- Joseph Flanagan PRE (49)
- Rachel Wilson CFO (49)
- John Sparby COO (45)
- Vijay Kotte EVP (43)
- Gary Long EVP (51)
- Jay Sreedharan CTO
- John Henneman LED (59)
- David Dill DRC (51)
- Anthony Speranzo DRC (72)
- Anthony Tersigni DRC (71)
- Albert Zimmerli DRC (69)
- Michael Feiner IND (78)
- Alex Mandl IND (77)
- Neal Moszkowski IND (55)
- Ian Sacks IND (50)
- Agnes Scanlan IND (63)
- Jill Smith IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- January 4th, 2022
- Public Since
- May 25th, 2010
- No. of Shareholders
- 30,019
- No. of Employees
- 29,400
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market
- Shares in Issue
- 422,394,189

- Address
- 434 W. Ascension Way, 6Th Floor, MURRAY, 84123
- Web
- https://www.r1rcm.com/
- Phone
- +1 3123247820
- Auditors
- Ernst & Young LLP
Upcoming Events for RCM
Q1 2025 R1 RCM Inc Earnings Release
Similar to RCM
Acadia Healthcare
NASDAQ Global Select Market
Accolade
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
FAQ
As of Today at 21:51 UTC, shares in R1 RCM are trading at $14.31. This share price information is delayed by 15 minutes.
Shares in R1 RCM last closed at $14.31 and the price had moved by +34.11% over the past 365 days. In terms of relative price strength the R1 RCM share price has outperformed the S&P500 Index by +2.44% over the past year.
The overall consensus recommendation for R1 RCM is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreR1 RCM does not currently pay a dividend.
R1 RCM does not currently pay a dividend.
R1 RCM does not currently pay a dividend.
To buy shares in R1 RCM you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $14.31, shares in R1 RCM had a market capitalisation of $6.04bn.
Here are the trading details for R1 RCM:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RCM
Based on an overall assessment of its quality, value and momentum R1 RCM is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in R1 RCM is $14.70. That is 2.73% above the last closing price of $14.31.
Analysts covering R1 RCM currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like R1 RCM. Over the past six months, its share price has outperformed the S&P500 Index by +4.6%.
As of the last closing price of $14.31, shares in R1 RCM were trading +8.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The R1 RCM PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $14.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
R1 RCM's management team is headed by:
- Joseph Flanagan - PRE
- Rachel Wilson - CFO
- John Sparby - COO
- Vijay Kotte - EVP
- Gary Long - EVP
- Jay Sreedharan - CTO
- John Henneman - LED
- David Dill - DRC
- Anthony Speranzo - DRC
- Anthony Tersigni - DRC
- Albert Zimmerli - DRC
- Michael Feiner - IND
- Alex Mandl - IND
- Neal Moszkowski - IND
- Ian Sacks - IND
- Agnes Scanlan - IND
- Jill Smith - IND